Spero Therapeutics, Inc.SPRONASDAQ

Revenue (LTM)

$48M

-53.8% YoY

Net Income (LTM)

$-69M

-400.6% YoY

Free Cash Flow

$-23M

Revenue CAGR (5Y)

+21.5%

Marginsimproving

FCF($0.0B)

Now unprofitable

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Revenue	9	3↓67.1%	49↑1482.4%	104↑113.6%	48↓53.8%
Gross Profit	-58	3↑105.3%	49↑1482.4%	52↑7.7%	-49↓193.2%
Operating Income	-79	-88↓11.2%	-42↑52.0%	21↑150.9%	-73↓441.5%
Net Income	-78	-90↓14.7%	-46↑48.3%	23↑149.1%	-69↓400.6%
EBITDA	-78	-87↓11.3%	-43↑50.7%	27↑163.2%	-72↓366.9%
EPS Diluted	-3.52	-2.91↑17.3%	-1.23↑57.7%	0.43↑135.0%	-1.27↓395.3%

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Cash & Equivalents	85	113↑32.1%	109↓3.1%	76↓30.0%	53↓30.7%
Total Current Assets	139	158↑13.5%	109↓30.9%	131↑20.3%	107↓18.2%
Total Assets	153	171↑11.5%	125↓27.0%	182↑46.1%	111↓39.4%
Total Current Liabilities	14	19↑30.2%	22↑16.0%	37↑71.6%	49↑32.1%
Total Liabilities	21	83↑286.6%	49↓41.0%	75↑54.5%	64↓14.7%
Total Equity	132	88↓33.1%	76↓14.0%	107↑40.8%	46↓56.9%
Total Debt	8	7↓6.4%	7↓9.4%	6↓16.6%	4↓22.5%
Net Debt	-77	-105↓36.0%	-102↑2.6%	-71↑30.9%	-49↑31.4%

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Operating Cash Flow	-86	-64↑25.1%	-8↑88.0%	-33↓326.8%	-23↑28.9%
Capital Expenditure	-0	64↑41085.3%	0	0	0
Free Cash Flow	-86	0	-8	-33↓326.8%	-23↑28.9%
Stock-Based Comp	5	0	0	8	8↓1.8%
Net Change in Cash	55	27↓50.7%	-3↓112.7%	-33↓842.6%	-23↑28.5%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance